Search clinical trials for: GSK HIV vaccine 732462

Total 895 results

Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

HIV-1 Infection
Novartis
Novartis Vaccines

Completed

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Meningitis | Meningococcal Infection

United States, China, Costa Rica, Guatemala, Panama, Peru
U.S. Army Medical Research and Development Command

Completed

Safety and Immunogenicity Study of Rift Valley Fever Vaccine (RVF)

Rift Valley Fever

United States
GlaxoSmithKline

Completed

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old

Infections, Meningococcal

Austria, Greece
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
Novartis Vaccines

Completed

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Meningitis, Meningococcal

United States, Argentina, Colombia
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

HPV Infection | HPV Vaccine | HIV-1-infection

Kenya
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

Influenza

Poland
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
GlaxoSmithKline

Terminated

A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

Human Papillomavirus Infection Leading to Cervical Cancer

Philippines
University of Colorado, Denver
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

The HPV 9-10 Trial: Early Initiation of HPV Vaccination

HPV

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
GlaxoSmithKline

Completed

Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control

Hepatitis B
Eastern Virginia Medical School
Merck Sharp & Dohme LLC

Unknown

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

Genital Human Papilloma Virus Infection

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

France, Poland
Hawaii Biotech, Inc.

Completed

Safety Study of HBV-002 West Nile Vaccine in Healthy Adults

West Nile Virus Disease

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

HIV Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
Bill & Melinda Gates Medical Research Institute
Iqvia Pty Ltd

Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Influenza
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
United Biomedical

Completed

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

HIV Infections

United States
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
Novartis Vaccines

Completed

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

Influenza

United States, Colombia, Panama, Philippines
GlaxoSmithKline

Completed

Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine

Hepatitis B
Merck Sharp & Dohme LLC

Completed

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Hepatitis B

Finland
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Suspended

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

HIV

United States
Sharon Riddler
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Autologous Dendritic Cell Vaccine in HIV1 Infection

HIV Infections

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

Infections, Streptococcal

Spain, Greece
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Hepatitis B
HIV Vaccine Trials Network

Completed

Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults

HIV Infections

Switzerland
Novartis Vaccines

Completed

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

Meningococcal Disease

United States, Australia, Canada
Assistance Publique - Hôpitaux de Paris
IREIVAC/COVIREIVAC Network

Active, not recruiting

Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults (COVIBOOSTAnci1)

COVID-19 Vaccines

France
GlaxoSmithKline

Completed

Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine

Hepatitis B

Germany, Belgium
Beijing Health Guard Biotechnology, Inc
University of Muhammadiyah Malang Hospital; Dr. M Djamil Hospital, Padang

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Human Papillomavirus Infection

Indonesia
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
Alessandro Ghelardi

Not yet recruiting

Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 (HOPE9)

Cervical Intraepithelial Neoplasia
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

HIV Infections

United States, Brazil, Haiti, Jamaica, South Africa
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
Sanofi

Completed

Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines

Pertussis | Tetanus | Diphtheria | Polio | Haemophilus Influenzae Type B

Philippines
National Institute of Allergy and Infectious Diseases...
Lederle-Praxis Biologicals

Completed

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

HIV Infections

United States
GlaxoSmithKline

Completed

Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib

Infections, Streptococcal

Netherlands

3

Subscribe